Talphera Inc. (TLPH)
0.61
-0.02 (-3.89%)
At close: Mar 24, 2025, 3:58 PM
0.63
3.22%
After-hours: Mar 24, 2025, 07:56 PM EDT
-3.89% (1D)
| Bid | 0.6 |
| Market Cap | 10.39M |
| Revenue (ttm) | 182.55K |
| Net Income (ttm) | -10.17M |
| EPS (ttm) | -0.7 |
| PE Ratio (ttm) | -0.87 |
| Forward PE | -1.04 |
| Analyst | Buy |
| Ask | 0.66 |
| Volume | 19,710 |
| Avg. Volume (20D) | 79,382 |
| Open | 0.63 |
| Previous Close | 0.63 |
| Day's Range | 0.59 - 0.64 |
| 52-Week Range | 0.50 - 1.27 |
| Beta | 0.20 |
About TLPH
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditi...
Sector Healthcare
IPO Date Feb 11, 2011
Employees 15
Stock Exchange NASDAQ
Ticker Symbol TLPH
Website https://talphera.com
Analyst Forecast
According to 2 analyst ratings, the average rating for TLPH stock is "Buy." The 12-month stock price forecast is $4.5, which is an increase of 637.70% from the latest price.
Stock Forecasts4 months ago
-25.61%
Talphera shares are trading lower. The company rep...
Unlock content with
Pro Subscription
7 months ago
-5.49%
Talphera shares are trading higher after the company reported better-than-expected Q2 EPS results.
